Telomere length is not altered in girls with idiopathic central precocious puberty treated with a GnRH analog - leuprolide acetate

What Was Tested

This observational study paper looks at Leuprolide.

To investigate the telomere length in iCPP girls treated with GnRHa.

Why It Was Studied

Idiopathic central precocious puberty (iCPP) presents a disproportionate advancement of bone age and maturation, as well as metabolic and endocrinological changes that may be related to effects on telomere biology.

Who Took Part

According to the abstract, 85 girls were involved.

The age groups tagged for this paper are children, teenagers and young adults, women only.

How the Study Was Run

Observational case-control study with 85 girls, including 45 iCPP treated with GnRHa and 40 controls.

It was analyzed age, height, weight and body mass index (BMI), insulin, triglycerides, testosterone, insulin resistance by HOMA, and telomere length by real-time PCR.

Statistical analyses were determined by Wilcoxon test and Spearman correlation was carried out.

What Was Measured

The subject headings attached to it are Age Factors, Body Composition, Body Mass Index, Case-Control Studies, Electric Impedance, Gonadotropin-Releasing Hormone and Insulin.

The authors tagged it with the keywords GnRH analog, Idiopathic central precocious puberty, leuprolide acetate, obesity and telomere length.

What This Means in Plain Language

This is a observational study of Leuprolide in 85 girls.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology), a journal based in England.

More context: the Leuprolide compound page, all human trials.